Spyre Therapeutics (SYRE) Receivables (2015 - 2024)
Spyre Therapeutics (SYRE) posted Receivables of $5.9 million for Q3 2024, little changed on a QoQ basis from $5.9 million in Q2 2024, and up 3519.63% year-over-year from $163000.0 in Q4 2023.
Spyre Therapeutics (SYRE) Receivables (2015 - 2024) Analysis & Trends
Spyre Therapeutics' Receivables history runs 8 years deep, the most recent figure standing at $5.9 million for Q3 2024.
- Quarterly Receivables rose 3519.63% year-over-year to $5.9 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $5.9 million (up 3519.63% YoY) and the FY2022 annual result came in at $375000.0, down 53.99% from the prior year.
- Receivables was $5.9 million for Q3 2024 at Spyre Therapeutics, roughly flat from $5.9 million in the prior quarter.
- Across five years, Receivables topped out at $21.5 million in Q1 2021 and bottomed at $163000.0 in Q3 2023.
- A 4-year average of $3.5 million and a median of $815000.0 in 2021 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables sank 95.29% — and 2024, when it soared 3519.63%.
- Spyre Therapeutics' Receivables stood at $815000.0 in 2021, then sank by 53.99% to $375000.0 in 2022, then sank by 56.53% to $163000.0 in 2023, then surged by 3519.63% to $5.9 million in 2024.
- Business Quant data shows SYRE's Receivables at $5.9 million in Q3 2024, $5.9 million in Q2 2024, and $163000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 5.90 Mn |
| Jun 30, 2024 | 5.90 Mn |
| Sep 30, 2023 | 163,000.00 |
| Jun 30, 2023 | 1.65 Mn |
| Mar 31, 2023 | 330,000.00 |
| Dec 31, 2022 | 375,000.00 |
| Sep 30, 2022 | 669,000.00 |
| Jun 30, 2022 | 479,000.00 |
| Mar 31, 2022 | 1.01 Mn |
| Dec 31, 2021 | 815,000.00 |
| Mar 31, 2021 | 21.50 Mn |
| Sep 30, 2018 | 2.42 Mn |
| Jun 30, 2018 | 4.28 Mn |
| Mar 31, 2018 | 3.37 Mn |
| Dec 31, 2017 | 3.08 Mn |
| Sep 30, 2017 | 2.45 Mn |
| Jun 30, 2017 | 1.21 Mn |
| Mar 31, 2017 | 981,000.00 |
| Dec 31, 2016 | 1.22 Mn |
| Sep 30, 2016 | 1.57 Mn |